{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:08:30Z","timestamp":1793916510456,"version":"4.8.0"},"reference-count":54,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T00:00:00Z","timestamp":1529539200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The National Institute on Aging\u2014Alzheimer's Association Research Framework on Alzheimer's disease (AD) represents an important advance in the biological characterization of the AD spectrum.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The National Institute on Aging\u2014Alzheimer's Association Framework is considered as it applies to clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Using the combination of amyloid (A), tau (T), and neurodegeneration (N) biomarkers, the Framework provides a means of defining the state of patients with regard to Alzheimer pathologic change. The Framework is relevant to clinical trials of disease\u2010modifying agents, allowing participants to be characterized biologically at baseline. The ATN Framework can also inform trial outcomes. The preclinical phase of the disease after amyloid deposition is defined by A+T\u2212N\u2212, and the transition to prodromal disease and dementia is characterized by the addition of T and N. Most symptomatic patients in clinical trials are in the class of A+T+N\u2212 and A+T+N+.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The National Institute on Aging\u2014Alzheimer's Association Framework on AD represents progress in providing biomarker profiles of participants in the AD spectrum that can be used to help design clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.jalz.2018.05.006","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T10:45:07Z","timestamp":1529577907000},"page":"172-178","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":136,"title":["The National Institute on Aging\u2014Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials"],"prefix":"10.1002","volume":"15","author":[{"given":"Jeffrey","family":"Cummings","sequence":"first","affiliation":[{"name":"Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas NV USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,21]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002923"},{"key":"e_1_2_6_4_2","first-page":"7060","article-title":"Early Alzheimer's Disease: Developing Drugs for Treatment; Draft Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2018","journal-title":"Federal Register"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9704"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-0059"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002892"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24546"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24186"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2006-9304"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2017.08.008"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004643"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.03.002"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24903"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww224"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21706"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25123"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2017.03.002"},{"key":"e_1_2_6_19_2","first-page":"781","article-title":"18F\u2010AV\u20101451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy","volume":"140","author":"Passamonti L","year":"2017","journal-title":"Brain"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-121594"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.03.003"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000144"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.6669"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2362"},{"key":"e_1_2_6_25_2","first-page":"748","article-title":"Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition","volume":"140","author":"Pontecorvo MJ","year":"2017","journal-title":"Brain"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx046"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0202"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2012-121489"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170129"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-179901"},{"key":"e_1_2_6_31_2","first-page":"109","article-title":"Defining disease modification for Alzheimer's disease clinical trials","volume":"4","author":"Cummings JL","year":"2017","journal-title":"J Prev Alzheimers Dis."},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-017-0096-2"},{"key":"e_1_2_6_33_2","first-page":"63","article-title":"Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease","volume":"14","author":"Mega MS","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol."},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.5.721"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318230a16c"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000159743.08996.99"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150448"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.03.004"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-142136"},{"key":"e_1_2_6_40_2","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.3233\/JAD-2012-129001","article-title":"Molecular mechanisms of amyloid oligomers toxicity","volume":"33","author":"Kayed R","year":"2013","journal-title":"J Alzheimers Dis."},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1386-3"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150247"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww139"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004887"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.2078"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2010.05.003"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2011.02.022"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2015.04.011"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2014.03.006"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1159\/000218080"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2016.37"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.3774"},{"key":"e_1_2_6_53_2","first-page":"190","article-title":"Correlations between antemortem hippocampal volume and postmortem neuropathology in AD subjects","volume":"18","author":"Csernansky JG","year":"2004","journal-title":"Alzheimer Dis Assoc Disord."},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm136"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.3881"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526018301602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526018301602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2018.05.006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2018.05.006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2018.05.006","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2018.05.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:51:29Z","timestamp":1759848689000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2018.05.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,21]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1016\/j.jalz.2018.05.006"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2018.05.006","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,21]]},"assertion":[{"value":"2018-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}